Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04903873 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
A Phase 1 study of Prostate Cancer and Non-Small Cell Lung Cancer, sponsored by Eutilex.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
- 6
- Study locations
NCT04903873: Recruiting Phase 1 study of Prostate Cancer and Non-Small Cell Lung Cancer, sponsored by Eutilex.
NCT04903873 is a Phase 1 study of Prostate Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by Eutilex. The registered enrollment target is 110 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (82% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04903873, a Phase 1 study of Prostate Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Eutilex.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
- 6
- Study locations
Study Summary
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG EU101
Study Locations (6)
Other
- National Cancer Center - Ilsan
- Samsung Seoul Hospital - Seoul
- Seoul Asan - Seoul
- Severance Hospital - Seoul
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Texas
- Mary Crowley Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2021-05-31 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What NCT04903873 shows while recruiting
NCT04903873 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (82% lower).
The record links to 5 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which EU101 is the first listed.
NCT04903873 lists 6 locations in 3 states (Other, Pennsylvania, Texas).
Frequently Asked Questions
What is clinical trial NCT04903873 about?
NCT04903873 is a clinical study titled "A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors". Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess t...
What is the current status of trial NCT04903873?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2021-05-31. Estimated completion is 2025-12.
What conditions does trial NCT04903873 study?
This clinical trial studies the following conditions: Prostate Cancer, Non-Small Cell Lung Cancer, Solid Tumor, Renal Cell Carcinoma, Renal Cell Cancer Metastatic.
What interventions are being tested in trial NCT04903873?
The interventions under investigation include: EU101 (DRUG).
Who is sponsoring clinical trial NCT04903873?
This trial is sponsored by Eutilex, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04903873 being conducted?
This trial has 6 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04903873's enrollment target sits among peer trials
110 320th of 735 higher than 415 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI